Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2006

01-07-2006 | Phase II Studies

Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy

Authors: Hitendra Patel, Ronald Stoller, Miklos Auber, Douglas Potter, Chao Cai, William Zamboni, Gauri Kiefer, Khalid Matin, Amy Schmotzer, Ramesh K. Ramanathan

Published in: Investigational New Drugs | Issue 4/2006

Login to get access
Metadata
Title
Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy
Authors
Hitendra Patel
Ronald Stoller
Miklos Auber
Douglas Potter
Chao Cai
William Zamboni
Gauri Kiefer
Khalid Matin
Amy Schmotzer
Ramesh K. Ramanathan
Publication date
01-07-2006
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 4/2006
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-006-6451-2

Other articles of this Issue 4/2006

Investigational New Drugs 4/2006 Go to the issue

Preclinical Studies

Population pharmacokinetics and bioavailability of motexafin gadolinium (Xcytrin®) in CD1 mice following intravenous and intraperitoneal injection

Phase II Studies

A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC)

Phase I Studies

A phase I Study with oral SU5416 in patients with advanced solid tumors: A drug inducing its clearance

Phase II Studies

SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group

Phase I Studies

A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors

Phase I Studies

A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits